Last reviewed · How we verify
NCT05025358
A Study of LP-118 in Patients With Advanced Tumors
Phase 1 trial testing LP-118 tablet in Solid Tumor in 68 participants. Completed in 9 July 2025.
9 July 2025
Quick facts
| Lead sponsor | Guangzhou Lupeng Pharmaceutical Company LTD. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 68 |
| Start date | 8 September 2021 |
| Primary completion | 9 July 2025 |
| Estimated completion | 9 July 2025 |
| Sites | 4 locations across China |
Drugs / interventions tested
- LP-118 tablet
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
- Lymphoma, Non-Hodgkin — all drugs for Lymphoma, Non-Hodgkin →
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD. — full company profile →
Who can join
18 and older, any sex, with Solid Tumor or Lymphoma, Non-Hodgkin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase I, multi-center, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-118 in patients with advanced malignancies, including solid tumors and lymphomas. LP-118 is a BCL-2/BCL-XL small molecule inhibitor.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins.
Pal P, Zhang P, Poddar SK, Zheng G. · · 2022 · cited 14× · PMID 35993382 · DOI 10.1080/13543776.2022.2116311 -
BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting.
Silva JPN, Pinto B, Silva PMA, Bousbaa H. · · 2026 · cited 1× · PMID 41596764 · DOI 10.3390/ijms27021123
Verify or expand the search:
- PubMed search for NCT05025358
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Other Guangzhou Lupeng Pharmaceutical Company LTD. trials
Trials by the same sponsor.
- NCT07374224 — A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet · Phase 1 · recruiting
- NCT07377578 — A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel · Phase 3 · recruiting
- NCT07189065 — A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma · Phase 2 · recruiting
- NCT06251180 — Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
- NCT06126861 — The Mass Balance Study of LP-168 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05025358 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Lupeng Pharmaceutical Company LTD.
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05025358.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing